Voltaren Emulgel 20mg/g gel for external use

Land: Armenien

Sprache: Englisch

Quelle: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Wirkstoff:

diclofenac (diclofenac diethylamine)

Verfügbar ab:

Novartis Consumer Health S.A.

ATC-Code:

M02AA15

INN (Internationale Bezeichnung):

diclofenac (diclofenac diethylamine)

Dosierung:

20mg/g

Darreichungsform:

gel for external use

Einheiten im Paket:

50g laminated tube, 100g laminated tube

Verschreibungstyp:

OTC

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2015-09-04

Gebrauchsinformation

I
Bo.ru.rnpeH 3Mym.reJib
2%
renT>
p,!ISI
Hapy?KHoro
npHMeHeHHSI,
JIHCTOR- BlOPM~M.5I
,ZVI5I
ITA~MEHTOB)
TOPROSOE UA3SAUUENPENAPATA:
BOllhTAPE~
3MYnhrEnh®
ME)KJ.EYLLAPO,!L;UOE
UENATEHTOBAUUOE UA3BANUE:
.D:HKJioeuru<
JLEKAPCMEUUAN
C}JOPMA:
reJII,
.n;JUI
uapy)KHoro npHMeuemm
2%
COCTAB:
B
1
r npenapaTa
co.n;ep)I(HTC51:
BY
AKTUBHOE
BEM:ECTBO:
23,2Mr
,!I;HKJIOeHrueHruHH
)KH)l;KHH,
OJieHJIOBhiH
CUHp
T,
3BKaJIHITTOBa51
QT.n;ymKa,
6yTHJirH.n;pOKCHTOJIYOJI,
npOITHJieHrJIHKOJih,
BO)l;a
QqHII.(eHHM:
ONUCAUUE:
M51rKHH,
o.n;uopo.n;Hhlii,
KpeMoo6pa3Hhili reJih,
[(BeT
oT
6enoro
.!1:0
)l(eJITosaroro.
«J)APMAKOTEPANEBTUQECKAB
RPYNNA
Cpe.n;crsa
.
.n;Jl51
Hapy)KHoro
npHMeHeHH51
npH
6oJI5~X
B cycrasax H Mhiiiii.(ax.
HecrepoH.n;Hbie
npomsosocnanHTeJihHhie
cpe.n.crsa
.n;AA
Hap)')I(Horo
npHMeHeHH51.
KO).L.
ATX:
M02AA15
«J)APMAKOJIORUQECKUCCBOHCTBA
WAPMAKOTJ:HHAMUKA
,[{HKJioeHru<
uecrepoH.n;uoe
npoTHBopesMarHqecKoe
cpe.n;crno
c
Bhipa)l(eHHbiM
aHanbrern:qecKHM,
npoTHBOBOCITaJIHTeJihHhiM
H
:aeHrueuaKa,
scacbmaiOmeroc5~
qepe3
Ko~,
nponopuHoHaJibHO
nnoma.n:u
o6pa6arhmaeMoii
nosepxuocrH
H
3aBHCHT
I~
JJ;O~!?lJlaHOCRMO
npenapara,
Ta.K
H .
OT
CTeUeHH
m.n;paTffilHH
I

Lesen Sie das vollständige Dokument

Fachinformation

Novartis Consumer Health SA
CH-1260 Nyon, Switzerland
Global Regulatory Affairs
VOLTAREN ®EMULGEL®
Gel
Diclofenac diethylamine 2.32%
F.AADI01
REGIONAL SUMMARY OF PRODUCT CHARACTERISTICS (SMPC)
Property of Novartis Consumer Health
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis Consumer Health
Novartis Consumer Health SA
CONFIDENTIAL
Page 2
EU-rSmPC
Voltaren Forte 2.32% gel
TABLE OF CONTENTS
1
NAME OF THE MEDICINAL PRODUCT
.......................................................................
3
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
............................................. 3
3
PHARMACEUTICAL FORM
............................................................................................
3
4
CLINICAL PARTICULARS
..............................................................................................
3
4.1
Therapeutic indications
............................................................................................
3
4.2
Posology and method of administration
.................................................................. 3
4.3
Contraindications
.....................................................................................................
4
4.4
Special warnings and precautions for use
................................................................ 5
4.5
Interaction with other medicinal products and other forms of
interaction .............. 5
4.6
Pregnancy and lactation
...........................................................................................
5
4.7
Effects on ability to drive and use machines
........................................................... 5
4.8
Undesirable effects
..................................................................................................
5
4.9
Overdose
..................................................................................................................
6
5
PHARMACOLOGICAL PROPERTIES
............................................................................
6